IRIS UniCatt

Chiricozzi, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.190
NA - Nord America 2.163
AS - Asia 1.824
SA - Sud America 405
AF - Africa 132
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 2
Totale 6.732
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.109
SG - Singapore 857
SE - Svezia 474
IT - Italia 458
CN - Cina 403
BR - Brasile 365
IE - Irlanda 314
DE - Germania 267
ID - Indonesia 216
FR - Francia 133
RU - Federazione Russa 131
CI - Costa d'Avorio 113
FI - Finlandia 98
GB - Regno Unito 93
IN - India 83
HK - Hong Kong 58
KR - Corea 56
NL - Olanda 39
CA - Canada 34
ES - Italia 33
JP - Giappone 24
AT - Austria 23
CZ - Repubblica Ceca 19
TR - Turchia 19
RO - Romania 16
AU - Australia 15
IQ - Iraq 14
AR - Argentina 13
CH - Svizzera 12
PK - Pakistan 11
PL - Polonia 10
TH - Thailandia 10
UA - Ucraina 10
BE - Belgio 9
IR - Iran 9
MX - Messico 9
VN - Vietnam 9
GR - Grecia 8
HU - Ungheria 7
PT - Portogallo 7
AE - Emirati Arabi Uniti 6
BD - Bangladesh 6
EC - Ecuador 6
IL - Israele 6
LT - Lituania 6
MA - Marocco 6
PE - Perù 6
BO - Bolivia 5
CO - Colombia 5
SA - Arabia Saudita 5
ZA - Sudafrica 5
HR - Croazia 4
RS - Serbia 4
TW - Taiwan 4
UZ - Uzbekistan 4
BG - Bulgaria 3
CL - Cile 3
CY - Cipro 3
DO - Repubblica Dominicana 3
JM - Giamaica 3
MY - Malesia 3
NP - Nepal 3
AL - Albania 2
AZ - Azerbaigian 2
EE - Estonia 2
EU - Europa 2
GE - Georgia 2
JO - Giordania 2
KE - Kenya 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
ME - Montenegro 2
NG - Nigeria 2
NO - Norvegia 2
PA - Panama 2
SI - Slovenia 2
AM - Armenia 1
BH - Bahrain 1
CR - Costa Rica 1
EG - Egitto 1
IM - Isola di Man 1
LB - Libano 1
LU - Lussemburgo 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
PS - Palestinian Territory 1
PY - Paraguay 1
QA - Qatar 1
SC - Seychelles 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
VE - Venezuela 1
ZW - Zimbabwe 1
Totale 6.732
Salva come PNG Salva come JPEG
Città #
Singapore 509
Ashburn 449
Chandler 425
Dublin 310
Jakarta 211
Milan 114
Abidjan 113
Bremen 113
New York 106
Moscow 103
Princeton 99
Beijing 81
Helsinki 79
Boston 76
Rome 75
Hong Kong 56
Hefei 53
Frankfurt am Main 50
Seoul 49
Wilmington 39
Los Angeles 38
Washington 31
San Mateo 30
Chicago 28
Nuremberg 28
Pune 28
London 27
The Dalles 26
São Paulo 23
Munich 22
Paris 22
Seattle 22
Hyderabad 19
Amsterdam 15
Brasília 15
Brno 15
Vienna 15
Hangzhou 14
Lappeenranta 14
Lauterbourg 14
Redwood City 14
Dearborn 13
North Bergen 13
Düsseldorf 12
Boardman 11
Roubaix 11
Belo Horizonte 10
Fairfield 10
Ottawa 10
Shanghai 10
Atlanta 9
Barcelona 9
Brussels 9
Montreal 9
Portsmouth 9
Toronto 9
Zurich 9
Boydton 8
Busto Arsizio 8
Chiang Mai 8
Nanjing 8
Naples 8
Norwalk 8
Bexley 7
Cattolica 7
Curitiba 7
Guangzhou 7
Houston 7
Mexico City 7
Rio de Janeiro 7
Tokyo 7
Ōtsu 7
Ankara 6
Edinburgh 6
Falkenstein 6
Madrid 6
Mumbai 6
Recife 6
Redmond 6
Stockholm 6
Sydney 6
Warsaw 6
Woodbridge 6
Andover 5
Bologna 5
Brooklyn 5
Chiyoda-ku 5
Council Bluffs 5
Feasterville Trevose 5
Iași 5
La Paz 5
Lima 5
Manaus 5
Monza 5
Porto Alegre 5
San Francisco 5
Sant Cugat del Vallès 5
Southampton 5
St Petersburg 5
Turku 5
Totale 3.995
Salva come PNG Salva come JPEG
Nome #
Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study 209
Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study 123
Clinical and ultrasonographic profile of adalimumab-treated hidradenitis suppurativa patients: A real-life monocentric experience 103
Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis 86
Improvement of severe facial seborrheic dermatitis following low-dose isotretinoin therapy 83
Assessment of alopecia areata universalis successfully treated with upadacitinib 79
Periocular molluscum contagiosum in an atopic dermatitis patient treated with upadacitinib 71
Therapeutic impact and management of persistent head and neck atopic dermatitis in dupilumab-treated patients 71
Expression of IL-23/Th17-related cytokines in basal cell carcinoma and in the response to medical treatments 70
Similar Levels of Efficacy of Two Different Maintenance Doses of Adalimumab on Clinical Severity and Quality of Life of Patients with Hidradenitis Suppurativa 68
Biological agents targeting interleukin-13 for atopic dermatitis 67
Case report: Dupilumab treatment improved type 2 disorders in a patient with IPEX syndrome diagnosis 66
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study 66
Disease Severity Is Associated with Alexithymia in Patients with Atopic Dermatitis 66
Dupilumab improves clinical manifestations, symptoms and quality of life in adult patients with chronic nodular prurigo 62
COVID-19 hygiene measures: hand eczema and insights into ACE2 and integrins as key molecules for SARS-CoV-2 cutaneous transmission 62
Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience 61
New JAK inhibitors for the treatment of psoriasis and psoriatic arthritis 61
A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis 61
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations 60
A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic 60
Successful Combination of Systemic Agents for the Treatment of Atopic Dermatitis Resistant to Dupilumab Therapy 60
Pediatric Hidradenitis Suppurativa: A Cross-Sectional Study on Clinical Features and Treatment Approaches 59
Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis 56
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 56
Long-term management of moderate-to-severe adult atopic dermatitis: A consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Association of Italian Territorial and Hospital Allergists and Immunologists (AAIITO), the Italian Association of Hospital Dermatologists (ADOI), the Italian Society of Allergological, Environmental and Occupational Dermatology (SIDAPA), and the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC) 56
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 55
Characterization of comorbid conditions burdening hidradenitis suppurativa: A multicentric observational study 55
Alopecia Areata Occurring after COVID-19 Vaccination: A Single-Center, Cross-Sectional Study 53
Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis 52
Flares as dynamic predictive factor of response to adalimumab in hidradenitis suppurativa: real-life data 52
The preclinical discovery and development of deucravacitinib for the treatment of psoriasis 52
European consensus statement on phenotypes of pustular psoriasis 52
Real-Time Confocal Imaging for Hidradenitis Suppurativa: Description of Morphological Aspects and Focus on the Role of Follicular Ostia 51
Real-Time Confocal Imaging for Hidradenitis Suppurativa: Description of Morphological Aspects and Focus on the Role of Follicular Ostia 51
Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year study 50
A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis 50
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 49
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 49
Successful treatment with secukinumab in an HIV-positive psoriatic patient after failure of apremilast 49
Alexithymia affects patients with hidradenitis suppurativa 49
Impact of Body Mass Index on the Efficacy of Biological Therapies in Patients with Psoriasis: A Real-World Study 49
Topical treatment of severe xerosis: Results of an observational study 49
Baricitinib: therapeutic potential for moderate to severe atopic dermatitis 48
Dupilumab-associated ocular adverse events are predicted by low tear break-up time and correlate with high IL-33 tear concentrations in patients with atopic dermatitis 47
Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis 47
COVID-19 occurrence in one secukinumab-treated patient affected by hidradenitis suppurativa and systemic lupus erythematosus 47
Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study 47
Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study 46
Factors related to the onset and recurrence of flares in hidradenitis suppurativa patients treated with adalimumab 46
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year 45
Investigational systemic drugs for moderate to severe plaque psoriasis: What's new? 44
Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis 44
Analysis of predictive factors influencing dupilumab continuation rate in adult patients with atopic dermatitis: results from an Italian multicenter study 43
Ixekizumab Effectiveness and Safety in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Multicenter, Retrospective Observational Study 43
Dusky red swelling of the penis in association with fever and diarrhoea: a quiz. Metastatic Crohn's disease of the penis associated with enteric Crohn's disease 43
Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry 42
Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study 42
Hidradenitis Suppurativa Associated with Down Syndrome Is Characterized by Early Age at Diagnosis 42
Novel Therapeutic Strategies in the Topical Treatment of Atopic Dermatitis 41
Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations 41
Certolizumab for the treatment of psoriasis and psoriatic arthritis: a real-world multicentre Italian study 41
Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy 41
Successful use of anti‐IL‐23 molecules in overweight‐to‐obese psoriatic patients: a multicentric retrospective study 40
Drug survival of biologics and non-biologics in patients affected by palmoplantar psoriasis: a “real-world”, mono-center experience 40
Mapping exercise and status update of eight established registries within the TREatment of ATopic eczema (TREAT) Registry Taskforce 39
Creation of a severity index for hidradenitis suppurativa that includes a validated quality-of-life measure: the HIDRAscore 39
The risk of covid-19 pandemic in patients with moderate to severe plaque psoriasis receiving systemic treatments 39
Authors’ reply to Borg and Thoning: “Comment on: Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study” 39
Effectiveness of Secukinumab in the treatment of moderate–severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real-life setting 39
Successful response to upadacitinib in the treatment of atopic dermatitis lesions involving sensitive and visible areas resistant to dupilumab treatment 37
Head and neck atopic dermatitis: still a challenging manifestation in the biologic era 37
The role of insomnia in the vulnerability to depressive and anxiety symptoms in atopic dermatitis adult patients 37
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis 37
Overview of Atopic Dermatitis in Different Ethnic Groups 36
AISI: A New Disease Severity Assessment Tool for Hidradenitis Suppurativa 36
Gynecomastia following isotretinoin treatment: A rare endocrine side effect 36
Gianotti-Crosti Syndrome after SARS-CoV-2 infection 35
Clinical, epidemiological, and therapeutic hallmarks of pyoderma gangrenosum: a case series of 35 patients 35
Immunologic biomarkers for clinical and therapeutic management of psoriasis 35
Bimekizumab 35
Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience 35
Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation 34
TSLP-activated dendritic cells induce human T follicular helper cell differentiation through OX40-ligand 34
Optimizing a clinical guidance for diagnosis of atopic dermatitis in adults: Joint recommendations of the Italian Society of Dermatology and Venereology (SIDeMaST), Italian Association of Hospital Dermatologists (ADOI), and Italian Society of Allergological, Occupational and Environmental Dermatology (SIDAPA) 34
Effectiveness and Safety of Upadacitinib in the Treatment of Moderate-Severe Atopic Dermatitis: A Multicentric, Prospective, Real-World, Cohort Study 34
Identification of clinical predictors for dupilumab dose spacing in adults with atopic dermatitis: a real-world study 33
Low grade of satisfaction related to the use of current systemic therapies among pustular psoriasis patients: a therapeutic unmet need to be fulfilled 32
Beneficial effects of upadacitinib on alopecia areata associated with atopic dermatitis: A multicenter retrospective study 32
Response to the article by Narla et al “Management of inadequate response and adverse effects to dupilumab in atopic dermatitis” 31
Coprevalence of Hidradenitis Suppurativa and Psoriasis: Detailed Demographic, Disease Severity and Comorbidity Pattern 31
The effects of systemic immunomodulatory treatments on COVID-19 outcomes in patients with atopic dermatitis: Results from the global SECURE-AD registry 30
Baricitinib: therapeutic potential for moderate to severe atopic dermatitis 30
Optimizing acitretin use in patients with plaque psoriasis 29
Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity 29
Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis 29
Drug survival of methotrexate and predictor factors for discontinuation in psoriasis 28
Current therapeutic paradigm in pediatric atopic dermatitis: Practical guidance from a national expert panel 28
Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris 28
The psychological burden during COVID-19 pandemic in a cohort of patients affected by moderate-to-severe atopic dermatitis treated with dupilumab 27
Totale 4.948
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.554
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 55.554
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202012 0 0 0 0 0 0 0 0 0 0 0 12
2020/202194 2 2 3 6 3 6 5 23 11 12 20 1
2021/2022466 47 2 13 11 17 4 8 45 20 96 91 112
2022/20231.894 152 189 143 311 100 235 150 176 233 61 103 41
2023/20241.859 45 374 116 272 85 252 121 90 39 93 147 225
2024/20252.455 60 40 286 66 283 129 92 93 492 251 597 66
Totale 6.905